In unveiling its latest round of collaborations, Johnson & Johnson Innovation LLC announced a collaboration with an option to acquire with Bird Rock Bio on a Phase I antibody targeting cannabinoid receptor 1 (CB1) that could mean the pharma’s entry into the crowded non-alcoholic steatohepatitis (NASH) space.
J&J revealed a spate of 15 collaborations underwritten by its innovation arm Jan. 5, in advance of next week’s JPMorgan Healthcare Conference
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?